Modeling and comparison of dissolution profiles for different brands of albendazole boluses

Mekasha, Yesuneh Tefera; Wondie Mekonen, Abibo; Nigussie, Sete; Usure, Rashed Edris; Feleke, Melaku Getahun

doi:10.1186/s40360-024-00774-2

BMC Pharmacol Toxicol

2024

DOI: 10.1186/s40360-024-00774-2

|View full text |Cite

Modeling and comparison of dissolution profiles for different brands of albendazole boluses

Yesuneh Tefera Mekasha,

Abibo Wondie Mekonen,

Sete Nigussie

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Studies on Risperidone Loaded β-Cyclodextrin Nanosponges for Managing Altered Mental Status and Delirium in Cancer Patients

Ahmed,

Ravi,

Pravallika

et al. 2024

J. Can. Res. Updates

View full text Add to dashboard Cite

This study explores the prospective of risperidone-loaded β-cyclodextrin nanosponges as a therapeutic strategy for managing altered mental status (AMS) and delirium in cancer patients. Almost 87% of patients with advanced cancer experience AMS or delirium, significantly impacting prognosis and quality of life. The present study aims to enhance the solubility, bioavailability, and therapeutic effectiveness of second-generation antipsychotic medication risperidone (RSP), with poor aqueous solubility, it was encapsulated in β-cyclodextrin nanosponges. The nanosponges prepared by fusion technique using different β-CD: DPC molar ratios, were tested for their ability to encapsulation efficiency, drug loading, and dissolutions kinetics. Batch 1, (1:1 molar ratio) exhibits RSP loading capacity (454.2 µg/mg) and encapsulation efficiency (90.84%) along with DSC and FTIR also confirmed that the RSP was successfully encapsulated and without any chemical interactions. In vitro dissolution studies demonstrated a biphasic release profile, with an initial burst followed by sustained release, governed by Fickian diffusion as confirmed by release kinetics modeling. The improved solubility and dissolution profile of the nanosponges will be significant to improve risperidone delivery, ensuring better symptom management in a vulnerable population. These findings highlight the potential of β-cyclodextrin nanosponges as an innovative and adaptable platform for enhancing antipsychotic drug delivery.

show abstract

Studies on Risperidone Loaded β-Cyclodextrin Nanosponges for Managing Altered Mental Status and Delirium in Cancer Patients

Ahmed,

Ravi,

Pravallika

et al. 2024

J. Can. Res. Updates

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Modeling and comparison of dissolution profiles for different brands of albendazole boluses

Cited by 1 publication

References 34 publications

Studies on Risperidone Loaded β-Cyclodextrin Nanosponges for Managing Altered Mental Status and Delirium in Cancer Patients

Studies on Risperidone Loaded β-Cyclodextrin Nanosponges for Managing Altered Mental Status and Delirium in Cancer Patients

Contact Info

Product

Resources

About